Vogenx Inc. priced an $81.3 million IPO aimed at funding continued development of mizagliflozin, its SGLT1 inhibitor in metabolic disease. The company said the drug is in development for post-bariatric hypoglycemia, gastroparesis, and GIP-dependent Cushing’s syndrome. The IPO is positioned to extend runway for clinical and regulatory activities across multiple indications, with mizagliflozin targeting intestinal glucose sensing through SGLT1 inhibition. For investors, the offering signals ongoing appetite for metabolic therapeutics with multi-indication clinical programs, even as capital markets remain selective. Vogenx’s stated use of proceeds centers on progressing the lead asset through its development plan.